Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770734 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2MAPK10BTKTRPV1 | |
| SCHEMBL19970083 | 0.89 | BTK (0.34) | HCRTR1HCRTR2BTKKRASMAPT | |
| SCHEMBL23770875 | 0.89 | BTK (0.34) | HCRTR1HCRTR2BTKKRASMAPT | |
| SCHEMBL23770834 | 0.88 | DGAT1 (0.36) | HCRTR1HCRTR2BTKDGAT1KCNH2 | |
| SCHEMBL23770671 | 0.86 | GALR2 (0.39) | MAPK10CNR1 | |
| SCHEMBL19927763 | 0.86 | HCRTR1 (0.34) | HCRTR1HCRTR2MAPK10BTKTRPV1 | |
| SCHEMBL19927760 | 0.86 | HCRTR1 (0.34) | HCRTR1HCRTR2MAPK10BTKTRPV1 | |
| SCHEMBL19970086 | 0.85 | DGAT1 (0.37) | HCRTR1HCRTR2BTKKRASMAPT | |
| SCHEMBL23770835 | 0.83 | PTPN11 (0.34) | MAPK10CNR1SCN10A | |
| SCHEMBL23770470 | 0.83 | DGAT1 (0.35) | BTKTRPV1DGAT1KCNH2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | HCRTR1 4258/4885HCRTR2 4087/4885MAPK10 3226/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | HCRTR1 4258/4885HCRTR2 4087/4885MAPK10 3226/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | HCRTR1 4258/4885HCRTR2 4087/4885MAPK10 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.